Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure [The Motley Fool]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: The Motley Fool
What happenedShares ofBlueprint Medicines(NASDAQ:BPMCThe disappointing results might settle the debate among investors over which company is better positioned to succeed in GIST: Blueprint Medicines orDeciphera PharmaceuticalsNASDAQ:DCPHAs of 0:8 a.m. EDT, thepharma stockImage source: Getty Images.So whatIn the phase trial conducted by Blueprint Medicines, 0 individuals received avapritinib and 6 individuals received regorafenib, which is approved as a third-line GIST treatment. The experimental therapy achieved a median PFS of . months, while the standard treatment achieved a median PFS of .6 months. The difference wasn't considered statistically significant.The top-line results suggest avapritinib might not be competitive as a second-line treatment option, for which Blueprint Medicines is currently conducting clinical trials. While a second-line GIST drug would have a larger market opportunity than later-line treatments, the bar for success is also higher. Sunitinib, the standard t
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics